Med-Chemist : "Quintessential Medicinal Chemistry"
Friday, January 20, 2017
Cranberries can reduce symptomatic UTIs and avoid chronic suppressive antibiotics
›
In continuation of my update on craneberries According to the study, recently published by the American Journal of Clinical Nutrit...
Thursday, January 19, 2017
Long-term dasatinib findings support first-line use in CML
›
In continuation of my update on dasatinib Final DASISION study findings confirm dasatinib to be an effective, long-term treatment for ...
Wednesday, January 18, 2017
Diabetes Drug Victoza May Help the Heart: Study
›
In continuation of my update on liraglutide T he blood sugar-lowering drug Victoza (liraglutide) cuts the risk of heart attack and ...
Tuesday, January 17, 2017
FDA Issues Complete Response Letter for Mycapssa New Drug Application
›
Chiasma, Inc. , a late-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, ...
Monday, January 16, 2017
Cempra Completes NDA Submissions for Solithromycin in the Treatment of Community-Acquired Bacterial Pneumonia
›
Cempra, Inc. , a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment ...
Friday, January 13, 2017
FDA Grants Soligenix “Fast Track” Designation for SGX943 for the Treatment of Melioidosis
›
Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to t...
Thursday, January 12, 2017
Charleston Laboratories, Inc. and Daiichi Sankyo, Inc. Announce FDA Acceptance of New Drug Application (NDA) for CL-108
›
In continuation of my updates on hydrocodone , Promethazine & acetaminophen Charleston Laboratories, Inc. and Daiichi Sankyo, I...
Wednesday, January 11, 2017
Shionogi Announces Acceptance of NDA for Naldemedine for the Treatment of Opioid-Induced Constipation
›
Shionogi announced that the New Drug Application (NDA) submitted in the U.S. for naldemedine , a once-daily, oral 0.2 mg tablet, has been ...
Tuesday, January 10, 2017
FDA Issues Complete Response Letter for Apadaz New Drug Application
›
KemPharm, Inc. a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, annou...
Monday, January 9, 2017
Allergan Announces FDA Acceptance of NDA Filing for Oxymetazoline HCI Cream 1.0%
›
Allergan plc announced that the New Drug Application (NDA) filing for oxymetazoline HCl cream 1.0%, an investigational topical prescript...
Friday, January 6, 2017
AstraZeneca Receives Complete Response Letter from FDA for Sodium Zirconium Cyclosilicate (ZS-9) for Hyperkalemia
›
AstraZeneca today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the ...
Thursday, January 5, 2017
Lexicon Announces FDA Priority Review of NDA for Telotristat Etiprate for the Treatment of Carcinoid Syndrome
›
Lexicon Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has accepted for filing the New Drug Application for t...
Wednesday, January 4, 2017
Radius Announces FDA Acceptance for Filing of NDA for for the Treatment of Postmenopausal Women with Osteoporosis
›
Radius Health, Inc. ), a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of ...
Tuesday, January 3, 2017
Teva Announces FDA Approval of ProAir RespiClick (albuterol sulfate) Inhalation Powder for Pediatric Asthma Patients Ages 4 to 11
›
Teva Pharmaceutical Industries Ltd., announced that the U.S. Food and Drug Administration (FDA) has approved ProAir RespiClick (albutero...
Monday, January 2, 2017
Flexion Therapeutics Receives Positive Guidance from FDA on NDA Submission for Zilretta for Osteoarthritis of the Knee
›
Flexion Therapeutics, Inc. announces that yesterday it received written responses from the U.S. Food & Drug Administration (FDA) to qu...
‹
›
Home
View web version